ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1246

Improving Radiologic Interpretation of Diffuse Lung Disease in Pediatric Rheumatologic (PR) Patients Using Trained Scoring with Semi-quantitative Chest Computed Tomography (CT) Analysis

Michal Cidon1, Beverley Newman2, Terry Robinson3, Paul Iskander4, Paul Thacker5, Evan Zucker2, Tzielan Lee6 and Rex Moats3, 1Children's Hospital Los Angeles, Los Angeles, CA, 2Stanford Children's Health, Stanford, CA, 3Children's Hospital of Los Angeles, Los Angeles, CA, 4University of California Los Angeles, Los Angeles, CA, 5Mayo Clinic, Rochester, MN, 6Stanford University School of Medicine, Palo Alto, CA

Meeting: ACR Convergence 2022

Keywords: Computed tomography (CT), Imaging, interstitial lung disease, Measurement Instrument, Pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Imaging of Rheumatic Diseases Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: We presented preliminary data in 2021 to support the feasibility of using a semi-quantitative chest CT scoring system (Pediatric Rheumatologic Diffuse Lung Disease Score [PRDLDS]) to evaluate the prevalence of diffuse lung disease (DLD) assessed by CT in pediatric rheumatologic patients. Our initial scoring data, after preliminary radiologic training, demonstrated mild parenchymal disease and no emphysema, but high inter-rater variability for parenchymal scoring in such patients. In addition, we noted inaccurate scoring based on the pulmonary hypertension (PHT) domain of the PRDLDS. The purpose of this follow-up study was to determine the effectiveness to improve the diagnostic performance of pediatric radiology scorers in evaluating lung disease in PR patients by providing more extensive training with a modified PRDLDS scoring system without pulmonary hypertension and emphysema (MPRDLDS, Table 1).

Methods: Initially three radiologists with varying DLD scoring experience independently read 1-2 mm inspiratory chest CT scans (96 non-contrast/24 Contrast) in 120 pediatric subjects (DG: N=42 PR patients with DLD; DCG: N=34 PR patients without DLD; and NCG: N=44 pediatric normal control subjects with chest CT scans) from 3 medical centers (Children’s Hospital of LA, Stanford Children’s Health, Mayo Clinic). After more extensive training with these radiologists using the MPRDLDS, they read 60 cases of the original 120 cases (DG: N=30; DCG: N=20; and NCG: N=10). We compared the scores before (N=120 cases) and after (N=60 cases) this training. Demographic and disease representation of the cases was similar between the groups (Table 2).

Results: With further training, there was overall more pronounced disease detected by all readers for the DG noted from initial scoring (N=120) to the follow-up scoring (N=60); there was also no significant difference between readers for aggregate parenchymal scores (MTPS) and total MPRDLDS (Table 3). In addition, control groups (DCG, DCG) previously evaluated to have minimal to no DLD were now evaluated to have essentially no DLD.

Conclusion: Semi-quantitative scoring using the MPRDLDS with more extensive training is a feasible tool to detect the extent of DLD in PR patients. Our data revealed that our PR patients have mild DLD which is primarily contributed by parenchymal disease. Due to the mild nature of this pulmonary disease, more extensive training of the readers with the MPRDLDS scoring system is crucial.

Supporting image 1

Table 1. Modified Pediatric Rheumatologic Diffuse Lung Disease Score (MPRDLDS)

Supporting image 2

Table 2. Patient Demographics and Disease

Supporting image 3

Table 3. Scoring Domains and Total Score for (MPRDLDS) Before (N=60) and After ( N=120) Training


Disclosures: M. Cidon, None; B. Newman, None; T. Robinson, None; P. Iskander, None; P. Thacker, None; E. Zucker, None; T. Lee, None; R. Moats, None.

To cite this abstract in AMA style:

Cidon M, Newman B, Robinson T, Iskander P, Thacker P, Zucker E, Lee T, Moats R. Improving Radiologic Interpretation of Diffuse Lung Disease in Pediatric Rheumatologic (PR) Patients Using Trained Scoring with Semi-quantitative Chest Computed Tomography (CT) Analysis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/improving-radiologic-interpretation-of-diffuse-lung-disease-in-pediatric-rheumatologic-pr-patients-using-trained-scoring-with-semi-quantitative-chest-computed-tomography-ct-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/improving-radiologic-interpretation-of-diffuse-lung-disease-in-pediatric-rheumatologic-pr-patients-using-trained-scoring-with-semi-quantitative-chest-computed-tomography-ct-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology